Introduction of 6,000 units represents single largest Alaris® contract outside the United States
Dubai, UAE - 25 January 2012: CareFusion, a leading global medical technology company, announces today that it has entered into an agreement with Abu Dhabi's Health Service Company (SEHA) for the largest single implementation contract outside the United States to install 6,000 Alaris® infusion channels across seven hospital locations in the Emirate of Abu Dhabi.
Anders Selin, Vice President and General Manager North, Central Europe, EMEA and West Asia at CareFusion stated: "We are delighted to continue enhancing our relationship with SEHA, which again demonstrates its leadership in addressing patient safety and achieve world-class standards for healthcare delivery. The GCC is a very important growth market for CareFusion and we look forward to strengthening our partnership with leading institutions and hospitals in the region."
The Alaris® medication safety systems help protect patients receiving intravenous infusions. It is a smart pump that helps protect every infusion, including intermittents, such as antibiotics and chemotherapy, and all infusion modalities, including large volume pump, PCA and syringe.
The three-year agreement, which came into effect late 2011 with implementation commencing with Al Rahba Hospital, also provides for in-depth training of clinicians in SEHA hospitals.
-Ends-
About CareFusion
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, Rowa™ automation solutions, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep®* skin prep products, MedMined™ services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.
This document is intended for audiences outside of the U.S.
*Products referred to in this release may not be available in all countries. Contact your local CareFusion office to check the availability of the registration licence and the prescribing information.
Contacts:
Media:
Annika Hjelm
+41 21 556 3106
annika.hjelm@carefusion.com
Investors: Jim Mazzola
+1 858 617 1203
jim.mazzola@carefusion.com
Hala Al Hadad
+971 4 390 2970
Hala.h@actiongroup.com
© Press Release 2012
